Cassie Barasch Ford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cassie Barasch Ford has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Melissa A. Greiner
Department of Population Health Sciences, Duke University School of Medicine , 215 Morris St, Durham, NC 27701, USA
3 shared publications - Amy G. Clark
Department of Population Health Sciences Duke University Durham North Carolina USA
2 shared publications - Chandler A. Long
Duke University Medical Center, Department of Orthopaedic Surgery, Durham, North Carolina
2 shared publications - Elizabeth Hope Weissler
Duke University Medical Center, Department of Orthopaedic Surgery, Durham, North Carolina
2 shared publications - Jay B. Lusk
Duke University School of Medicine
2 shared publications - Kim G. Johnson
Duke University
2 shared publications
Latest Publications
- 5 August 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 275-283
Neighborhood Socioeconomic Deprivation and Adherence to Diabetic Retinopathy Screening Guidelines
- 5 August 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 275-283
Neighborhood Socioeconomic Deprivation and Adherence to Diabetic Retinopathy Screening Guidelines
- 1 May 2025
- Published by Human Kinetics in International Journal of Athletic Therapy and Training
- Vol. 30 (3) , 155-162
Influence of Sensory Integration and Visual Performance on Postural Control Under Differing Levels of Visual Occlusion in Those With Chronic Ankle Instability
Individuals with chronic ankle instability (CAI) have postural control deficits and appear to be more reliant on visual information to maintain balance. The underlying cause of this visual reliance remains unknown. Our purpose was to determine how sensory integration and visual performance influence postural control under different visual occlusion levels in those with CAI. Sensory integration ability, as measured by the Sensory Organization Test, was not associated with postural control in those with CAI. Visual performance variables, such as perception span, depth perception, and target capture explained between 13% and 45% of postural control variance across visual occlusion levels. The results suggest that improving visual performance in those with CAI may improve postural control across levels of visual occlusion.
- 1 May 2025
- Published by Human Kinetics in International Journal of Athletic Therapy and Training
- Vol. 30 (3) , 155-162
Influence of Sensory Integration and Visual Performance on Postural Control Under Differing Levels of Visual Occlusion in Those With Chronic Ankle Instability
Individuals with chronic ankle instability (CAI) have postural control deficits and appear to be more reliant on visual information to maintain balance. The underlying cause of this visual reliance remains unknown. Our purpose was to determine how sensory integration and visual performance influence postural control under different visual occlusion levels in those with CAI. Sensory integration ability, as measured by the Sensory Organization Test, was not associated with postural control in those with CAI. Visual performance variables, such as perception span, depth perception, and target capture explained between 13% and 45% of postural control variance across visual occlusion levels. The results suggest that improving visual performance in those with CAI may improve postural control across levels of visual occlusion.
- 1 April 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (2) , e200273
Racial Disparities in Low-Value Care in the Last Year of Life for Medicare Beneficiaries With Neurodegenerative Disease
There are racial disparities in health care services received by patients with neurodegenerative diseases, but little is known about disparities in the last year of life, specifically in high-value and low-value care utilization. This study evaluated racial disparities in the utilization of high-value and low-value care in the last year of life among Medicare beneficiaries with dementia or Parkinson disease. This was a retrospective, population-based cohort analysis using data from North and South Carolina fee-for-service Medicare claims between 2013 and 2017. We created a decedent cohort of beneficiaries aged 50 years or older at diagnosis with dementia or Parkinson disease. Specific low-value utilization outcomes were selected from the Choosing Wisely initiative, including cancer screening, peripheral artery stenting, and feeding tube placement in the last year of life. Low-value outcomes included hospitalization, emergency department visits, neuroimaging services, and number of days receiving skilled nursing. High-value outcomes included receipt of occupational and physical therapy, hospice care, and medications indicated for dementia and/or Parkinson disease. Among 70,650 decedents, 13,753 were Black, 55,765 were White, 93.1% had dementia, and 7.7% had Parkinson disease. Adjusting for age, sex, Medicaid dual enrollment status, rural vs urban location, state (NC and SC), and comorbidities, Black decedents were more likely to receive low-value care including colorectal cancer screening (adjusted hazard ratio [aHR] 1.46 [1.32-1.61]), peripheral artery stenting (aHR 1.72 [1.43-2.08]), and feeding tube placement (aHR 2.96 [2.70-3.24]) and less likely to receive physical therapy (aHR 0.73 [0.64-0.85)], dementia medications (aHR 0.90 [0.86-0.95]), or Parkinson disease medications (aHR 0.88 [0.75-1.02]) within the last year of life. Black decedents were more likely to be hospitalized (aHR 1.28 [1.25-1.32]), more likely to be admitted to skilled nursing (aHR 1.09 [1.05-1.13]), and less likely to be admitted to hospice (aHR 0.82 [0.79-0.85]) than White decedents. We found racial disparities in care utilization among patients with neurodegenerative disease in the last year of life, such that Black decedents were more likely to receive specific low-value care services and less likely to receive high-value supportive care than White decedents, even after adjusting for health status and socioeconomic factors.
- 1 April 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (2) , e200273
Racial Disparities in Low-Value Care in the Last Year of Life for Medicare Beneficiaries With Neurodegenerative Disease
There are racial disparities in health care services received by patients with neurodegenerative diseases, but little is known about disparities in the last year of life, specifically in high-value and low-value care utilization. This study evaluated racial disparities in the utilization of high-value and low-value care in the last year of life among Medicare beneficiaries with dementia or Parkinson disease. This was a retrospective, population-based cohort analysis using data from North and South Carolina fee-for-service Medicare claims between 2013 and 2017. We created a decedent cohort of beneficiaries aged 50 years or older at diagnosis with dementia or Parkinson disease. Specific low-value utilization outcomes were selected from the Choosing Wisely initiative, including cancer screening, peripheral artery stenting, and feeding tube placement in the last year of life. Low-value outcomes included hospitalization, emergency department visits, neuroimaging services, and number of days receiving skilled nursing. High-value outcomes included receipt of occupational and physical therapy, hospice care, and medications indicated for dementia and/or Parkinson disease. Among 70,650 decedents, 13,753 were Black, 55,765 were White, 93.1% had dementia, and 7.7% had Parkinson disease. Adjusting for age, sex, Medicaid dual enrollment status, rural vs urban location, state (NC and SC), and comorbidities, Black decedents were more likely to receive low-value care including colorectal cancer screening (adjusted hazard ratio [aHR] 1.46 [1.32-1.61]), peripheral artery stenting (aHR 1.72 [1.43-2.08]), and feeding tube placement (aHR 2.96 [2.70-3.24]) and less likely to receive physical therapy (aHR 0.73 [0.64-0.85)], dementia medications (aHR 0.90 [0.86-0.95]), or Parkinson disease medications (aHR 0.88 [0.75-1.02]) within the last year of life. Black decedents were more likely to be hospitalized (aHR 1.28 [1.25-1.32]), more likely to be admitted to skilled nursing (aHR 1.09 [1.05-1.13]), and less likely to be admitted to hospice (aHR 0.82 [0.79-0.85]) than White decedents. We found racial disparities in care utilization among patients with neurodegenerative disease in the last year of life, such that Black decedents were more likely to receive specific low-value care services and less likely to receive high-value supportive care than White decedents, even after adjusting for health status and socioeconomic factors.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Neuropsychiatric co‐morbidities and psychotropic medication use in Medicare beneficiaries with dementia
Background: Neuropsychiatric symptoms affect approximately 97% of patients with dementia. Prevalence of symptoms may be different dependent upon age, sex or race. Past studies report high rates of potentially inappropriate prescribing in the dementia population. We investigate differences in neuropsychiatric diagnoses and psychotropic medication prescribing in a local US cohort.Method: We utilize Medicare claims and Medicare Part D prescription fill records in a cohort of 100% Medicare North and South Carolina fee‐for‐service beneficiaries ages 50 and above for the year 2017 with a dementia diagnosis. We identify dementia based on an ICD‐10‐CM diagnosis of dementia from an inpatient, outpatient, carrier, skilled nursing facility or home health claim, or a prescription claim for drug treatment between 1/1/2017 and 12/31/2017. We quantified neuropsychiatric diagnosis of anxiety, depression and psychosis using validated coding algorithms, searching inpatient, outpatient and physician 2017 claims. Demographic characteristics, including age, sex and race, as well as dual Medicare/Medicaid status were collected from the MSBF file for each individual. We search generic medication names in Medicare Part D claims for anti‐anxiety, antidepressant and antipsychotic medications to determine prescriptions filled during 2017.Result: Providers diagnosed anxiety and depression at higher rates in White patients; and psychosis at higher rates in Black patients. (P<0.001) Providers diagnosed female patients with depression, anxiety and psychosis at higher rates than males. (P<0.001) A provider diagnosis of anxiety, depression or psychosis is most prevalent in the age group 50‐59 and decreases with age to age 90+. Females with anxiety, depression and psychosis filled more anti‐anxiety and antidepressant medications than males. (P<0.001) Black and Other race patients filled more antipsychotic medications for anxiety and depression than White patients. (P benefits in this population and lack efficacy. As alternatives, non‐pharmacologic treatment with patient/caregiver education about expectations and psychosocial interventions show promise. Innovative community outreach and care delivery models incorporating these methods may help decrease levels of medication use.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessNeuropsychiatric co‐morbidities and psychotropic medication use in Medicare beneficiaries with dementia
Background: Neuropsychiatric symptoms affect approximately 97% of patients with dementia. Prevalence of symptoms may be different dependent upon age, sex or race. Past studies report high rates of potentially inappropriate prescribing in the dementia population. We investigate differences in neuropsychiatric diagnoses and psychotropic medication prescribing in a local US cohort.Method: We utilize Medicare claims and Medicare Part D prescription fill records in a cohort of 100% Medicare North and South Carolina fee‐for‐service beneficiaries ages 50 and above for the year 2017 with a dementia diagnosis. We identify dementia based on an ICD‐10‐CM diagnosis of dementia from an inpatient, outpatient, carrier, skilled nursing facility or home health claim, or a prescription claim for drug treatment between 1/1/2017 and 12/31/2017. We quantified neuropsychiatric diagnosis of anxiety, depression and psychosis using validated coding algorithms, searching inpatient, outpatient and physician 2017 claims. Demographic characteristics, including age, sex and race, as well as dual Medicare/Medicaid status were collected from the MSBF file for each individual. We search generic medication names in Medicare Part D claims for anti‐anxiety, antidepressant and antipsychotic medications to determine prescriptions filled during 2017.Result: Providers diagnosed anxiety and depression at higher rates in White patients; and psychosis at higher rates in Black patients. (P<0.001) Providers diagnosed female patients with depression, anxiety and psychosis at higher rates than males. (P<0.001) A provider diagnosis of anxiety, depression or psychosis is most prevalent in the age group 50‐59 and decreases with age to age 90+. Females with anxiety, depression and psychosis filled more anti‐anxiety and antidepressant medications than males. (P<0.001) Black and Other race patients filled more antipsychotic medications for anxiety and depression than White patients. (P benefits in this population and lack efficacy. As alternatives, non‐pharmacologic treatment with patient/caregiver education about expectations and psychosocial interventions show promise. Innovative community outreach and care delivery models incorporating these methods may help decrease levels of medication use.
- 1 December 2021
- Published by Elsevier in American Heart Journal
- Vol. 242, 6-14
Younger patients with chronic limb threatening ischemia face more frequent amputations
- 1 December 2021
- Published by Elsevier in American Heart Journal
- Vol. 242, 6-14
Younger patients with chronic limb threatening ischemia face more frequent amputations
- 7 October 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (2) , 219-227
Clinician Specialty, Access to Care, and Outcomes Among Patients with Peripheral Artery Disease
- 7 October 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (2) , 219-227
Clinician Specialty, Access to Care, and Outcomes Among Patients with Peripheral Artery Disease